CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation
of engineered T cell therapeutics that employ phagocytic and innate immune system mechanisms, announces it is presenting preclinical data on its lead product candidate CER-1236 at the Stanford Drug
Discovery Symposium, which is being held April 29-30, 2024 in Palo Alto, Calif.
The poster, titled, “TIM-4-L-targeting CER-1236 Engineered T cells Eliminate Adverse-Risk AML Xenografts and Exhibit Favorable Manufacturing Product Attributes for Clinical Translation,” outlines key attributes of the program. Specifically, the data highlights the capabilities of CER-1236 engineered T cells in eliminating adverse-risk p53mutated AML cell lines in vivo and low risk of off-tumor toxicity to hematopoietic progenitor stem cells (HSPCs). The poster also highlights manufacturing data demonstrating the Company’s capacity to generate high yields of CER-1236 drug product exhibiting naïve and central memory phenotypes, which enhance the activity of the therapy. Details of the poster can be found here.
CERo Founder and CTO Daniel Corey comments, “CER-1236 engineered T cells targeting TIM-4-L are a novel and differentiated therapeutic approach for leukemia with encouraging pre-clinical data. We have demonstrated the capacity to manufacture high yields of CER-1236 with favorable memory and immunophenotypic profiles. We are diligently working on an IND submission in the near term. We look forward to continuing to provide appropriate updates to shareholders as they develop.”
Lesen Sie auch
About CERo Therapeutics, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering,
which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to
achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ
phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford
them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid
tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.